2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome.

The unique characteristics of patients with chronic coronary syndrome (CCS) in the Asia-Pacific region, heterogeneous approaches because of differences in accesses and resources and low number of patients from the Asia-Pacific region in pivotal studies, mean that international guidelines cannot be routinely applied to these populations. The Asian Pacific Society of Cardiology developed these consensus recommendations to summarise current evidence on the management of CCS and provide recommendations to assist clinicians treat patients from the region. The consensus recommendations were developed by an expert consensus panel who reviewed and appraised the available literature, with focus on data from patients in Asia-Pacific. Consensus statements were developed then put to an online vote. The resulting recommendations provide guidance on the assessment and management of bleeding and ischaemic risks in Asian CCS patients. Furthermore, the selection of long-term antithrombotic therapy is discussed, including the role of single antiplatelet therapy, dual antiplatelet therapy and dual pathway inhibition therapy.

Informations de copyright

Copyright © 2021, Radcliffe Cardiology.

Déclaration de conflit d'intérêts

Disclosure: This work was funded through the Asian Pacific Society of Cardiology with unrestricted educational grants from Abbott Vascular, Amgen, AstraZeneca, Bayer and Roche Diagnostics. JWCT reports honoraria from AstraZeneca, Bayer, Amgen, Medtronic, Abbott Vascular, Biosensors, Alvimedica, Boehringer Ingelheim and Pfizer; research and educational grants from Medtronic, Biosensors, Biotronik, Philips, Amgen, AstraZeneca, Roche, Otsuka, Terumo and Abbott Vascular; and consulting fees from Elixir and CSL Behring. DPC reports consulting fees from the Asian Pacific Society of Cardiology (APSC); support for travel to meetings for the study or otherwise from APSC; grants/grants pending from Roche Diagnostics; and payment for development of educational presentations, including service on speakers’ bureaus from AstraZeneca. DB reports honoraria from AstraZeneca, Bristol-Myers Squibb and Pfizer. JA reports honoraria from AstraZeneca, Daiichi Sankyo, Bayer and Sanofi; and grants/grants pending from Daiichi Sankyo. GM reports research grants to the Institution or consulting/lecture fees from Abbott, Amgen, Actelion, American College of Cardiology Foundation, AstraZeneca, Axis-Santé, Bayer, Boston Scientific, Boehringer Ingelheim, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women’s Hospital, Idorsia, Elsevier, Fédération Française de Cardiologie, Frequence Medicale, ICAN, Lead-Up, Medtronic, Menarini, MSD, Pfizer, Quantum Genomics, Sanofi, SCOR Global Life, Servier and WebMD. DKQ reports honoraria from Bayer and Pfizer. HFT reports research grants or consulting/lecture fees from Abbott, Amgen, AstraZeneca, Bayer, Boston Scientific, Boehringer Ingelheim, Biosense Webster, Daiichi Sankyo, Pfizer, Sanofi and Servier. KAAF reports research grants from Bayer and AstraZeneca; and consulting/lecture fees from Bayer/Janssen, Sanofi/Regeneron and Verseon. SJA reports honoraria from Bayer. CKC reports speaker or advisory attracting travel expenses or honoraria from Amgen, AstraZeneca and Bayer. SL reports lecture honoraria from Bristol-Myers Squibb, Bayer and Boehringer-Ingelheim; proctorship fees from Abbott, Boston Scientific and Bioexcel; research funding from Abbot; and is an advisory board member for Abbott and Medtronic. HIY has been a speaker for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Lilly, Mitsubishi Tanabe, Novartis, MSD, Orient Europharma, Pfizer and Sanofi. All other authors have no conflicts of interest to declare.